Effects of exercise on schizophrenia symptoms and quality of life for patients on clozapine
Investigating the Effect of Exercise on Clinical Symptoms, Cognitive Performance, and Quality of Life in Schizophrenia Patients Treated With Clozapine
NA · Dr. Lutfi Kirdar Kartal Training and Research Hospital · NCT06573320
This study tests if regular exercise can improve symptoms and quality of life for people with schizophrenia who are taking clozapine.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Dr. Lutfi Kirdar Kartal Training and Research Hospital (other gov) |
| Locations | 1 site (Istanbul) |
| Trial ID | NCT06573320 on ClinicalTrials.gov |
What this trial studies
This study investigates how physical exercise impacts clinical symptoms, cognitive performance, and overall quality of life in patients with schizophrenia who are being treated with clozapine. The research focuses on individuals diagnosed with schizophrenia according to DSM-V criteria and receiving a therapeutic dose of clozapine. By assessing the effects of exercise, the study aims to provide insights into potential non-pharmacological interventions that could enhance treatment outcomes for these patients.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with schizophrenia who are currently being treated with a therapeutic dose of clozapine.
Not a fit: Patients who are pregnant will not benefit from this study due to exclusion criteria.
Why it matters
Potential benefit: If successful, this study could improve the management of schizophrenia symptoms and enhance the quality of life for patients on clozapine.
How similar studies have performed: While the approach of combining exercise with pharmacological treatment in schizophrenia is gaining interest, this specific study's focus on clozapine is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients treated who were diagnosed with schizophrenia according to DSM-V criteria by psychiatrist at the Turkish Ministry of Health Kartal Dr. Lütfi Kırdar City Hospital * using a therapeutic dose of 300-500 mg/day of clozapine, Exclusion Criteria: * pregnancy
Where this trial is running
Istanbul
- Kartal Dr Lütfi Kırdar Şehir Hastanesi — Istanbul, Turkey (Türkiye) (RECRUITING)
Study contacts
- Study coordinator: Ebru Akbuga Koc
- Email: ebruakbuga@gmail.com
- Phone: 0216
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Schizophrenia, Clozapine, Exercise